{"entity":{"id":"idea-reg-third-party-label-update","kind":"idea","name":"Let non-profits and academics add a cancer indication to an off-patent drug's label","aka":[],"tldr":"Only the manufacturer can ask regulators to add a new use to a drug's label, and generic makers have no reason to. Universities and charities should be allowed to apply.","summary":"When a publicly funded trial proves an old drug works in cancer, the result rarely reaches the label because no marketing authorisation holder will file, leaving the indication off-label with weak reimbursement and guideline status. The EU's 2023 pharmaceutical reform proposal includes a mechanism for non-commercial entities to submit evidence for a new indication, which the regulator can then require all holders to include; the FDA has no equivalent. The proposal is a formal third-party supplement pathway in FDA, EMA and other regulators, with fee waivers, allowing academic sponsors to file, and a label change binding on all generic versions.","asOf":"2026-09-08","links":[{"label":"EU pharmaceutical legislation reform","url":"https://health.ec.europa.eu/medicinal-products/pharmaceutical-strategy-europe/reform-eu-pharmaceutical-legislation_en"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-generic-repurposing","b-regulatory-fragmentation"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"Within five years of the pathway opening, at least five off-patent drugs gain oncology indications through third-party filings, and reimbursement and guideline adoption of those indications follow within a year of labelling.","rationale":"The label is the hinge on which reimbursement, guidelines and prescribing turn; a pathway that decouples label updates from the commercial interest of the holder removes the last barrier for proven repurposed drugs.","test":"Pass the EU provision and pilot an FDA equivalent; file the first two academic supplements (for example a positive repurposing trial result) and measure time to label change and downstream reimbursement.","maturity":"early-clinical","actor":"regulator","cost":"small","horizonYears":4},"route":"/ideas/idea-reg-third-party-label-update/","neighbours":{"bottleneck":[{"id":"b-generic-repurposing","kind":"bottleneck","name":"No incentive to repurpose cheap drugs","route":"/bottlenecks/b-generic-repurposing/"},{"id":"b-regulatory-fragmentation","kind":"bottleneck","name":"Regulatory divergence between regions","route":"/bottlenecks/b-regulatory-fragmentation/"}]}}